Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial

Contemporary Clinical Trials

Volumn 32, Issue 2, 2011, Pages 178-187

  Mahaffey, Kenneth W ^a   Wampole, June L ^a   Stebbins, Amanda ^a   Berdan, Lisa G ^a   McAfee, Donna ^b   Rorick, Tyrus L ^a   French, John K ^c   Kleiman, Neal S ^d   O'Connor, Christopher M ^a   Cohen, Eric A ^e   Granger, Christopher B ^a   Armstrong, Paul W ^f  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^c LIVERPOOL HOSPITAL   (Australia)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Cardiogenic shock; Clinical event classification; Clinical trials; Congestive heart failure; End point adjudication

Indexed keywords

PEXELIZUMAB;

ACUTE HEART INFARCTION; ALGORITHM; ARTICLE; CARDIOGENIC SHOCK; CLASSIFICATION; CLINICAL EVENT CLASSIFICATION; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DATA ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH;

ANTIBODIES, MONOCLONAL; BUNDLE-BRANCH BLOCK; CARDIOVASCULAR AGENTS; DIAGNOSIS, COMPUTER-ASSISTED; DOUBLE-BLIND METHOD; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MYOCARDIAL INFARCTION; OBSERVER VARIATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, CARDIOGENIC; SINGLE-CHAIN ANTIBODIES; TIME FACTORS;

EID: 79551565534     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2010.12.013     Document Type: Article

References (9)

1. Petersen J.L., Haque G., Hellkamp A.S., Flaker G.C., Mark Estes N.A., Marchlinski F.E., et al. Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee. Contemp Clin Trials 2006, 27:260-268.
2. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 1980, 302:250-256. The Anturane Reinfarction Trial Research Group.
3. Temple R., Pledger G.W. The FDA's critique of the Anturane Reinfarction Trial. N Engl J Med 1980, 303:1488-1492.
4. Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House Classification. EDTRS report number 10. Ophthalmology 1991, 98:786-806. Early Treatment Diabetic Retinopathy Study Research Group.
5. Mahaffey K.W., Harrington R.A., Akkerhuis M., Kleiman N.S., Berdan L.G., Crenshaw B.S., et al. Systematic adjudication of myocardial infarction end points in an international clinical trial. Curr Control Trials Cardiovasc Med 2001, 2:180-186.
6. Armstrong P.W., Granger C.B., Adams P.X., Hamm C., Holmes D., et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007, 297:43-51. APEX AMI Investigators.
7. Armstrong P.W., Adams P.X., Al-Khalidi H.R., Hamm C., Holmes D., O'Neill W., et al. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 2005, 149:402-407.
8. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000, 356:2037-2044. ESPRIT Investigators.
9. Mahaffey K.W., Roe M.T., Dyke C.K., Newby L.K., Kleiman N.S., Connolly P., et al. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Am Heart J 2002, 143:242-248.